Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide

Neuron

Volumn 97, Issue 1, 2018, Pages 92-107.e10

  Zunke, Friederike ^a   Moise, Alexandra C ^a   Belur, Nandkishore R ^a   Gelyana, Eilrayna ^a   Stojkovska, Iva ^a   Dzaferbegovic, Haris ^a   Toker, Nicholas J ^a   Jeon, Sohee ^a   Fredriksen, Kristina ^a   Mazzulli, Joseph R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Gaucher disease; GBA1; glucocerebrosidase; iPS derived dopaminergic neurons; Lewy body; lysosomal storage disease; Parkinson's disease; protein aggregation; synuclein

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GAUCHER DISEASE; GBA1 GENE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; MESENCEPHALON; MOLECULAR WEIGHT; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEPLETION; CELL CULTURE; CHEMISTRY; METABOLISM; PATHOLOGY;

ALPHA-SYNUCLEIN; CELLS, CULTURED; DOPAMINERGIC NEURONS; GLUCOSYLCERAMIDES; GLYCOSPHINGOLIPIDS; HUMANS; MESENCEPHALON; PARKINSON DISEASE;

EID: 85040558820     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2017.12.012     Document Type: Article

References (57)

1. Alcalay, R.N., Levy, O.A., Waters, C.C., Fahn, S., Ford, B., Kuo, S.H., Mazzoni, P., Pauciulo, M.W., Nichols, W.C., Gan-Or, Z., et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 138 (2015), 2648–2658.
2. Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q., Iwatsubo, T., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152 (1998), 879–884.
3. Bartels, T., Choi, J.G., Selkoe, D.J., α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 (2011), 107–110.
4. Bessen, R.A., Kocisko, D.A., Raymond, G.J., Nandan, S., Lansbury, P.T., Caughey, B., Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 375 (1995), 698–700.
5. Bielawski, J., Pierce, J.S., Snider, J., Rembiesa, B., Szulc, Z.M., Bielawska, A., Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Adv. Exp. Med. Biol. 688 (2010), 46–59.
6. Bligh, E.G., Dyer, W.J., A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 (1959), 911–917.
7. Buell, A.K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T.P., Linse, S., Dobson, C.M., Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc. Natl. Acad. Sci. USA 111 (2014), 7671–7676.
8. Burré J., Sharma, M., Südhof, T.C., α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl. Acad. Sci. USA 111 (2014), E4274–E4283.
9. Cole, N.B., Murphy, D.D., Grider, T., Rueter, S., Brasaemle, D., Nussbaum, R.L., Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem. 277 (2002), 6344–6352.
10. Cremades, N., Cohen, S.I., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal, M., Clarke, R.W., Dunne, P., Aprile, F.A., et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149 (2012), 1048–1059.
11. Davidson, W.S., Jonas, A., Clayton, D.F., George, J.M., Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 (1998), 9443–9449.
12. Dettmer, U., Newman, A.J., Soldner, F., Luth, E.S., Kim, N.C., von Saucken, V.E., Sanderson, J.B., Jaenisch, R., Bartels, T., Selkoe, D., Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun., 6, 2015, 7314.
13. Dettmer, U., Selkoe, D., Bartels, T., New insights into cellular α-synuclein homeostasis in health and disease. Curr. Opin. Neurobiol. 36 (2016), 15–22.
14. Duda, J.E., Giasson, B.I., Mabon, M.E., Lee, V.M., Trojanowski, J.Q., Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 52 (2002), 205–210.
15. Eisele, Y.S., Monteiro, C., Fearns, C., Encalada, S.E., Wiseman, R.L., Powers, E.T., Kelly, J.W., Targeting protein aggregation for the treatment of degenerative diseases. Nat. Rev. Drug Discov. 14 (2015), 759–780.
16. Farfel-Becker, T., Vitner, E.B., Kelly, S.L., Bame, J.R., Duan, J., Shinder, V., Merrill, A.H. Jr., Dobrenis, K., Futerman, A.H., Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum. Mol. Genet. 23 (2014), 843–854.
17. Gegg, M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J., Wood, N.W., Schapira, A.H., Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72 (2012), 455–463.
18. Giasson, B.I., Murray, I.V., Trojanowski, J.Q., Lee, V.M., A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001), 2380–2386.
19. Glabe, C.G., Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283 (2008), 29639–29643.
20. Goedert, M., Spillantini, M.G., Del Tredici, K., Braak, H., 100 years of Lewy pathology. Nat. Rev. Neurol. 9 (2013), 13–24.
21. Goker-Alpan, O., Schiffmann, R., LaMarca, M.E., Nussbaum, R.L., McInerney-Leo, A., Sidransky, E., Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41 (2004), 937–940.
22. Gould, N., Mor, D.E., Lightfoot, R., Malkus, K., Giasson, B., Ischiropoulos, H., Evidence of native α-synuclein conformers in the human brain. J. Biol. Chem. 289 (2014), 7929–7934.
23. Grabowski, G.A., Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372 (2008), 1263–1271.
24. Guo, J.L., Covell, D.J., Daniels, J.P., Iba, M., Stieber, A., Zhang, B., Riddle, D.M., Kwong, L.K., Xu, Y., Trojanowski, J.Q., Lee, V.M., Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154 (2013), 103–117.
25. Han, H., Weinreb, P.H., Lansbury, P.T. Jr., The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?. Chem. Biol. 2 (1995), 163–169.
26. Hedrich, K., Hagenah, J., Djarmati, A., Hiller, A., Lohnau, T., Lasek, K., Grünewald, A., Hilker, R., Steinlechner, S., Boston, H., et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?. Arch. Neurol. 63 (2006), 833–838.
27. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003), 486–489.
28. Kriks, S., Shim, J.W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480 (2011), 547–551.
29. Lansbury, P.T. Jr., Structural neurology: are seeds at the root of neuronal degeneration?. Neuron 19 (1997), 1151–1154.
30. Lee, R.E., The fine structure of the cerebroside occurring in Gaucher's disease. Proc. Natl. Acad. Sci. USA 61 (1968), 484–489.
31. Liu, C., Zhao, M., Jiang, L., Cheng, P.N., Park, J., Sawaya, M.R., Pensalfini, A., Gou, D., Berk, A.J., Glabe, C.G., et al. Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates. Proc. Natl. Acad. Sci. USA 109 (2012), 20913–20918.
32. Luth, E.S., Bartels, T., Dettmer, U., Kim, N.C., Selkoe, D.J., Purification of α-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry 54 (2015), 279–292.
33. Mazzulli, J.R., Mishizen, A.J., Giasson, B.I., Lynch, D.R., Thomas, S.A., Nakashima, A., Nagatsu, T., Ota, A., Ischiropoulos, H., Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26 (2006), 10068–10078.
34. Mazzulli, J.R., Armakola, M., Dumoulin, M., Parastatidis, I., Ischiropoulos, H., Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 282 (2007), 31621–31630.
35. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A., Krainc, D., Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 (2011), 37–52.
36. Mazzulli, J.R., Zunke, F., Isacson, O., Studer, L., Krainc, D., α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc. Natl. Acad. Sci. USA 113 (2016), 1931–1936.
37. Mazzulli, J.R., Zunke, F., Tsunemi, T., Toker, N.J., Jeon, S., Burbulla, L.F., Patnaik, S., Sidransky, E., Marugan, J.J., Sue, C.M., Krainc, D., Activation of β-glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons. J. Neurosci. 36 (2016), 7693–7706.
38. McEachern, K.A., Fung, J., Komarnitsky, S., Siegel, C.S., Chuang, W.L., Hutto, E., Shayman, J.A., Grabowski, G.A., Aerts, J.M., Cheng, S.H., et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol. Genet. Metab. 91 (2007), 259–267.
39. Murphy, K.E., Gysbers, A.M., Abbott, S.K., Tayebi, N., Kim, W.S., Sidransky, E., Cooper, A., Garner, B., Halliday, G.M., Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 137 (2014), 834–848.
40. Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., Zimran, A., Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89 (1996), 691–694.
41. Ran, F.A., Hsu, P.D., Lin, C.Y., Gootenberg, J.S., Konermann, S., Trevino, A.E., Scott, D.A., Inoue, A., Matoba, S., Zhang, Y., Zhang, F., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154 (2013), 1380–1389.
42. Roberts, R.F., Wade-Martins, R., Alegre-Abarrategui, J., Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 138 (2015), 1642–1657.
43. Rocha, E.M., Smith, G.A., Park, E., Cao, H., Brown, E., Hallett, P., Isacson, O., Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann. Clin. Transl. Neurol. 2 (2015), 433–438.
44. Schöndorf, D.C., Aureli, M., McAllister, F.E., Hindley, C.J., Mayer, F., Schmid, B., Sardi, S.P., Valsecchi, M., Hoffmann, S., Schwarz, L.K., et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun., 5, 2014, 4028.
45. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361 (2009), 1651–1661.
46. Siebert, M., Sidransky, E., Westbroek, W., Glucocerebrosidase is shaking up the synucleinopathies. Brain 137 (2014), 1304–1322.
47. Stroud, J.C., Liu, C., Teng, P.K., Eisenberg, D., Toxic fibrillar oligomers of amyloid-β have cross-β structure. Proc. Natl. Acad. Sci. USA 109 (2012), 7717–7722.
48. Takahashi, K., Naito, M., Lipid storage disease: Part II. Ultrastructural pathology of lipid storage cells in sphingolipidoses. Acta Pathol. Jpn. 35 (1985), 385–408.
49. Tsika, E., Moysidou, M., Guo, J., Cushman, M., Gannon, P., Sandaltzopoulos, R., Giasson, B.I., Krainc, D., Ischiropoulos, H., Mazzulli, J.R., Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J. Neurosci. 30 (2010), 3409–3418.
50. Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L.T., Liao, J., Auclair, J.R., Johnson, D., Landeru, A., Simorellis, A.K., et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. USA 108 (2011), 17797–17802.
51. Wang, L., Das, U., Scott, D.A., Tang, Y., McLean, P.J., Roy, S., α-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 24 (2014), 2319–2326.
52. Waxman, E.A., Duda, J.E., Giasson, B.I., Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 116 (2008), 37–46.
53. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., Lansbury, P.T. Jr., NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996), 13709–13715.
54. Willemsen, R., Tybulewicz, V., Sidransky, E., Eliason, W.K., Martin, B.M., LaMarca, M.E., Reuser, A.J., Tremblay, M., Westphal, H., Mulligan, R.C., et al. A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse. Mol. Chem. Neuropathol. 24 (1995), 179–192.
55. Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K., Morrison, A., Lwin, A., Colegial, C., Allman, J.M., Schiffmann, R., Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82 (2004), 192–207.
56. Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M., Biere, A.L., alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274 (1999), 19509–19512.
57. Yap, T.L., Velayati, A., Sidransky, E., Lee, J.C., Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet. Metab. 108 (2013), 56–64.